Dual And Multi Energy Computed Tomography Market Outlook On The Basis Of Application, Type, End-Use, Region And Forecast to 2030: Grand View Research Inc.

San Francisco, 11 July 2023: The Report Dual And Multi Energy Computed Tomography Market Size, Share & Trends Analysis Report By Type (Prospective, Retrospective), By End-use (Ambulatory Imaging Centers, Hospitals), By Application, By Region, And Segment Forecasts, 2023 – 2030

The global dual and multi energy computed tomography market size is expected to reach USD 1.51 billion by 2030, registering a CAGR of 7.3% over the forecast period, according to a new report by Grand View Research, Inc. Continuous focus on the introduction of technologically advanced devices, increasing chronic disorders like cancer, orthopedics, cardiological or neurological conditions, and increasing prevalence of aging population, are expected to propel the growth of the industry. According to the data from the National Institutes of Health (NIH), patients aged 65 years and above undergo diagnostic imaging at a rate twice or thrice that of the younger population.

Dual Source Computed Tomography (DSCT) is gaining large scope in recent times due to improved temporal resolution for ECG-synchronized cardiac scanning, improved spectral separation by additional pre-filtration of the high-kV beam, reduced cross-scattering, and improved dual-energy contrast. The system uses two X-ray tubes and two detectors at 90°. DSCT can be operated at twice the spiral pitch of single-source CT. The dual-source CT allows the interrogation of materials that have different attenuation properties at different energies. In recent years, there has been increased utilization of Dual-energy CT (DECT) in diagnostic imaging, mainly due to a reduction of effective radiation dose and lower intravenous contrast dose requirement in DECT imaging compared to conventional CT.

Access Research Report of Dual And Multi Energy Computed Tomography Market @ https://www.grandviewresearch.com/industry-analysis/dual-multi-energy-computed-tomography-market-report

Dual And Multi Energy Computed Tomography Market Report Highlights

• Asia Pacific accounted for the largest market share in 2022. This can be attributable to the increasing incidence of chronic conditions and the high adoption of advanced imaging modalities.
• The oncology application segment accounted for the largest share in 2022
• The hospital end-use segment accounted for the largest share in 2022 due to ongoing research studies and economic capabilities
• The COVID-19 pandemic led to a decline in research activities, the closure of universities & academic institutions, and a decline in clinical trial activities. The fear of virus spread also declined any diagnostic or surgical activities at end-use settings
• The economic crunch at hospitals and diagnostic centers or clinics led to the reduced adoption of software and systems for non-invasive diagnosis. Thus, the pandemic led to a decline in the market in 2020

Dual And Multi Energy Computed Tomography Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 914.29 million
Revenue forecast in 2030	USD 1.51 billion
Growth rate	CAGR of 7.3% from 2023 to 2030
Base year for estimation	2022
Historical data	2018 – 2021
Forecast period	2023 – 2030

List of Key Players of Dual And Multi Energy Computed Tomography Market

• Koninklijke Philips N.V.
• GE Healthcare
• Siemens Healthineers
• Canon Medical Systems
• Fujifilm Holdings Corp.
• Shimadzu Corp.
• Koning Corp.
• Neusoft Medical Systems Co. Ltd.
• CareStream Health
• Planmeca Group
• Hitachi Healthcare Systems
• Stryker Corp.

Access Press Release of Dual And Multi Energy Computed Tomography Market @ https://www.grandviewresearch.com/press-release/global-dual-multi-energy-computed-tomography-market

U.S. Clinical Oncology Next Generation Sequencing Market Size Is Anticipated To Reach USD 1.53 Billion By 2024: Grand View Research Inc.

San Francisco, 27 April 2023: The Report U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow, By End Use, Regions, And Segment Forecasts 2018 To 2024

The U.S. clinical oncology next generation sequencing market is anticipated to reach USD 1.53 billion by 2024, according to a new report by Grand View Research, Inc. Applications of NGS platform for clinical oncology are expected to grow at a steady pace under the influence of increasing adoption of NGS platforms in oncology R&D coupled with rising incidents of cancer.

Application of NGS based cancer diagnostics for screening and monitoring of oncogenes to understand the underlying mechanism behind causes of cancer is expected to boost the growth of this vertical throughout the forecast period.

Moreover, exponentially decreasing costs for sequencing have also spurred the demand for NGS platform in clinical oncology research as whole genome analysis has become affordable even by the smaller R&D entities. In addition, high competition amongst prominent market players to enhance their share in the market is also expected to translate into increased revenues generated by these companies as a result.

Access Research Report of U.S. Clinical Oncology Next Generation Sequencing Market @ https://www.grandviewresearch.com/industry-analysis/us-clinical-oncology-next-generation-sequencing-ngs-market

Further key findings from the report suggest:

• Out of the different technologies offered by NGS platforms, targeted sequencing & resequencing accounted for the largest share owing to the fact that it enables the study of changes in diseases at molecular level, & analyze the underlying modifications in the genetic sequence to investigate epigenomics of cancer, thus enhancing demand for more advancement in targeted sequencing tools.
• The workflow associated with genomic sequencing is expected to witness lucrative progress as a result of variation in platforms provided by prominent market players with respect to amount of DNA sequenced per cycle, read length, and runtime. Furthermore, data analysis of raw sequence data thus obtained, is the most critical step in the workflow of NGS, and is thus anticipated to experience immense growth in the coming years as a consequence of the abundance of data generated post-sequencing.
• Adoption of high throughput sequencing platform by clinical sector is observed to be more promising for NGS based oncology research market as a consequence of the usage of NGS in cancer research and more specifically in the discovery of new cancer-related genes, tumor heterogeneity, and identification of alterations that are contributive in tumorogenesis
• Key players operating in this industry include Illumina Inc., Roche, Agilent Technologies, Knome Incorporated. Genomatix Software GmbH, GATC Biotech Ag, Oxford Nanopore Technologies Ltd, Macrogen Inc., Life Technologies Corp, DNASTAR Inc, Exosome Diagnostics, Biomatters Ltd, CLC Bio, BGI, Qiagen NV, Perkin Elmer, Incorporated, Pacific Bioscience, Inc, Partek, Inc, GnuBIO, Foundation Medicine, Paradigm, Caris Life Sciences and Myriad Genetics and they are actively engaged in manufacturing and commercialization of innovative bioinformatics algorithms as demonstrated by the increasingly growing number of partnerships between prominent players and emerging players.
• For instance, In February 2016, Thermo Fisher collaborated with Invivoscribe Technologies, Inc for the development of NGS based, in vitro diagnostic (IVD) oncology tests on Ion PGM Dx System which is further anticipated to accelerate the growth of the company in near future. Similarly, in June 2016, Thermo Fisher supported enhancement and commercialization of clinical research assay and in vitro diagnostics using NGS technology launched the Ion Torrent Developers Alliance Program.

Access Press Release of U.S. Clinical Oncology Next Generation Sequencing Market @ https://www.grandviewresearch.com/press-release/us-clinical-oncology-next-generation-sequencing-ngs-market-analysis

Cellular Health Screening Market Size Worth $3.47 Billion By 2028: Grand View Research Inc.

San Francisco, 5 July 2021: The Report Cellular Health Screening Market Size, Share & Trends Analysis Report By Test Type (Single Test Panels, Multi-test Panels), By Sample Test (Blood, Saliva) By Collection Sites (Home, Hospitals), And Segment Forecasts, 2021 – 2028

The global cellular health screening market size is expected to reach USD 3.47 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 6.3% from 2021 to 2028. The rising adoption of telomere performance programs and increased awareness regarding the importance of Healthy Adjusted Life Expectancy (HALE) are anticipated to be major factors boosting the market growth during the forecast period. In the recent past, an increasing number of individuals have been utilizing cellular health screening tests, such as telomere tests, to understand biomarkers of cell aging. Tests such as those facilitating insights into telomere length and activity have proven to provide data on lifestyle and stress factors.

Several studies have proved that chronic and acute stress causes cell aging. Physical activity, sleep & psychological disorders, and drinking & smoking habits cause changes in cellular aging differently. The use of telomere test provides insights into metabolic and genetic diseases providing clinicians with early diagnosis and timely & personalized treatment plans for patients. Thus, rising awareness and growing research surrounding cellular screening have led to increased demand for kits and tests, facilitating market growth in recent years.

The need for research on cellular screening has increased owing to its various uses in preventive health and its ability to understand correlations between telomere length and aging. Bio cell-based screenings are mostly recommended over a period of time, facilitating patients to compare results and understand what changes are to be undertaken. Tracking these changes in cellular health in between screenings facilitates immediate changes to be implemented in terms of health protocols and overall improvement of disease management.

Furthermore, the accumulation of old malfunctioning cells is associated with age-related illnesses. Research has now proven that these can be reversed using several cellular health techniques as demonstrated in various animal studies. Thus, continuous research and development in the fields of genomics, proteomics, and protein expression are anticipated to further boost market growth.

Access Research Report of Cellular Health Screening Market @ https://www.grandviewresearch.com/industry-analysis/cellular-health-screening-market

Cellular Health Screening Market Report Highlights

• The introduction of advanced cell health screening tests and rising awareness about the importance of HALE are responsible for the market growth
• Based on test type, single test panels accounted for the largest revenue share in 2020 owing to their high use in key markets
• Based on collection sites, the home segment is projected to register the fastest CAGR of more than 7% over the forecast period
• North America was the largest regional market in 2020 due to high awareness about preventative healthcare and quick adoption of technologically advanced products in the U.S.
• Asia Pacific is anticipated to exhibit the fastest CAGR over the forecast period due to the growing geriatric population in countries, such as Japan, China, and India

List of Key Players of Cellular Health Screening Market

• Telomere Diagnostics
• SpectraCell Laboratories
• Life Length
• Repeat Diagnostics, Inc.
• Cell Science Systems Corp.
• Quest Diagnostics
• LabCorp Holdings
• OPKO
• Genova Diagnostics
• Immunodiagnostik AG
• DNA Labs

Access Press Release of Cellular Health Screening Market @ https://www.grandviewresearch.com/press-release/global-cellular-health-screening-market

Clinical Laboratory Service Market is Predicted to Observe a Tremendous Growth, With a CAGR of 4.7% From 2021 To 2028: Grand View Research Inc.

San Francisco, 15 Feb 2021: The Report Clinical Laboratory Service Market Size, Share & Trends Analysis Report By Test Type (Human & Tumor Genetics, Clinical Chemistry, Medical Microbiology & Cytology), By Service Provider, By Application, By Region, And Segment Forecasts, 2021 – 2028

The global clinical laboratory service market size is expected to reach USD 288.7 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 4.7% from 2021 to 2028. Growing prevalence of target diseases such as diabetes and cardiovascular diseases is expected to positively impact the market growth over the forecast period. For instance, according to the WHO, by 2030, cardiovascular diseases are estimated to cause approximately 23.6 million deaths, mainly from heart disease and stroke.

The COVID-19 pandemic, caused due to SARS-CoV-2, is affecting millions of people globally. According to WHO and CDC, the standard for laboratory diagnosis of COVID-19 is Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for samples collected from the respiratory tract. The adoption of PCR technology for the diagnosis of COVID-19 and the genetic sequencing of the virus for the development of a cure are driving the market.

Furthermore, in May 2020, the Department of Health and Human Services (HHS) provided more than USD 200 million to clinics in rural areas of the U.S. to expedite COVID-19 testing. Such robust investments by government bodies to increase adoption of COVID-19 diagnostic kits by clinics are anticipated to boost segment growth. COVID-19 walk-up clinics in San Jose are another key initiative expected to positively impact segment growth.

In addition, advancements in laboratory testing technology through incremental and breakthrough developments are expected to serve this market as a high impact rendering driver. For instance, in March 2020, a Singapore-based med-tech company, Biolidics, launched a rapid test kit for COVID-19 and entered into a manufacturing agreement with a diagnostic kit manufacturer for mass production.

Automation in clinical settings has significantly improved the data management process in labs. Improving adoption rates of laboratory automation systems is expected to boost the market throughout the forecast period. Furthermore, database management tools, patient test records, and integrated workflow management systems have received significant consideration in the healthcare industry.

Access Research Report of Clinical Laboratory Service Market @ https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-services-market

Clinical Laboratory Service Market Report Highlights

• In 2020, the clinical chemistry segment held majority of revenue share owing to presence of large number of tests due to increasing knowledge on clinical chemistry
• Stand-alone laboratories is expected to witness lucrative growth rate over the forecast period due to introduction of digital support systems to manage large databases and ability to provide better clinical laboratory services at a comparatively lower rate
• The bioanalytical and lab chemistry services segment dominated the market in 2020 owing to rising use of wide range of techniques and technology platforms to fulfill diagnostic needs
• In Asia Pacific, the market is projected to witness the fastest growth over the forecast period owing to a growing awareness, increased government initiatives, and positive regulatory policies
• North America dominated the market in 2020 due to technological advancements and high awareness on medical standards

List of Key Players of Clinical Laboratory Service Market

• Qiagen
• OPKO Health, Inc.
• Charles River Laboratories
• International, Inc
• Sonic Healthcare
• Almac Group
• Laboratory Corporation of America Holdings (LabCorp)
• DaVita, Inc.
• Viapath Group LLP
• Abbott
• SGS SA
• Quest Diagnostics, Inc.
• NeoGenomics Laboratories, Inc.
• Siemens Healthcare GmbH
• Fresenius Medical Care
• Cinven
• Arup Laboratories

Access Press Release of Clinical Laboratory Service Market @ https://www.grandviewresearch.com/press-release/global-clinical-laboratory-services-market

Blood Transfusion Diagnostics Market Projected To Expand At A CAGR 6.6% For The Forecast Period From 2020 To 2027: Grand View Research Inc.

San Francisco, 3 Dec 2020: The Report Blood Transfusion Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Kits, Instruments), By Application (Blood Grouping, Disease Screening), By End Use (Hospitals, Blood Banks) And Segment Forecasts, 2020 – 2027

The global blood transfusion diagnostics market size is expected to reach a value of USD 5.8 billion by 2027 registering a CAGR of 6.6%, according to a new report by Grand View Research, Inc. Growing prevalence of chronic diseases, such as anemia, sickle cell disease, hemophilia, cancer, and kidney disease, is significantly driving the market growth. According to the Sickle Cell Disease Coalition statistics, globally, the number of sickle cell disease cases is projected to increase by around 30% by 2050.According to NCBI statistics, liver diseases accounts for around 2 million deaths each year globally. Blood transfusion is crucial for patients with such chronic diseases, as it allows to exchange the diseased cells with the healthy RBCs without disrupting the blood viscosity.

According to the National Blood Transfusion Service (NBTS) database, a total of 60,236 donor screening was done between 2010 and 2016 at the National Blood Transfusion Center (NBTC), Eritrea. Among them, at least 3.6% of the donated blood showed positive results for TTI and 0.1% showed positive results for multiple infections. Some of the chronic infectious diseases, such as hepatitis B, hepatitis C, HIV, and syphilis, create the need for accurate donor screening, thus further driving the market growth of diagnostics. Transfusion is commonly used in cases of trauma, road accidents, surgeries, childbirth, and gastrointestinal bleeding to replace major blood losses.

Access Research Report of Blood Transfusion Diagnostics Market @ https://www.grandviewresearch.com/industry-analysis/blood-transfusion-diagnostics-market

Blood Transfusion Diagnostics Market Report Highlights

• Reagents and kits is expected to be the largest as well as the fastest-growing product segment from 2020 to 2027
• The disease screening segment is projected to register the fastest CAGR over the forecast period
• According to the WHO, screening of donated blood for detecting transfusion transmissible infections, such as hepatitis B & C and HIV, should be mandatory
• The hospitals end-use segment is estimated to account for the second largest market share by 2027 on account of rising instances of Pretransfusion therapies being performed in hospitals as the therapy requires cross-matching tests between the donor and recipient
• Asia Pacific is projected to be the fastest-growing regional market due to rising geriatric population, especially in China and Japan

List of Key Players of Blood Transfusion Diagnostics Market

• Grifols S.A.
• Immucor, Inc.
• Ortho Clinical Diagnostics
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Hoffmann-La Roche Ltd.
• Quotient Ltd.

Access Press Release of Blood Transfusion Diagnostics Market @ https://www.grandviewresearch.com/press-release/global-blood-transfusion-diagnostics-market

Hematology Diagnostics Market Size Is Expected To Reach USD 9.39 Billion By 2025: Grand View Research Inc.

San Francisco, 10 Nov 2020: The Report Hematology Diagnostics Market Size, Share & Trends Analysis Report By Product (Instrument, Consumables), By Test Type (Blood Count, Platelet Function, Hemoglobin, Hematocrit), And Segment Forecasts, 2018 – 2025

The global hematology diagnostics market size is expected to reach USD 9.39 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.85% over the forecast period. Increasing prevalence of blood disorders coupled with adoption of automated testing processes are projected to propel the market growth.

Automation of hematology diagnostics process have led to reduced turnaround time thereby accelerating the overall treatment regimen. Furthermore, automation has also led to reduced administrative errors and overall costs of diagnostic tests. Thus, it is expected to boost growth of the hematology testing market in the forthcoming years.

Dominance of hematology analyzers can be attributed to the presence of fully-automated analyzers which are objective, have high-throughput, and are cost-effective. Furthermore, these hematology analyzers can also detect atypical results and can improve measurable parameters such as red cell distribution width, platelet distribution, Reticulocyte (RET) counts, and nucleated red cells counts.

The advent of Point-Of-Care (PoC) hematology testing devices has led to improved diagnostic and patient outcomes. These devices are user-friendly and are available for use outside the hospital settings. This is anticipated to increase the acceptability and accessibility of hematology testing which, in turn, is anticipated to propel market growth.

Product recall and intense market competition leading to price wars are anticipated to hinder market growth. In 2018, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes owing to chemical interference with certain tests. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA), thereby indicating that the use of these devices may cause serious injuries or death. Such product recalls can negatively affect the market growth.

Access Research Report of Hematology Diagnostics Market @ https://www.grandviewresearch.com/industry-analysis/hematology-diagnostics-market

Further key findings from the report suggest:

• Consumables emerged as the largest segment owing to increasing testing and diagnosis of blood disorders
• Diagnostic labs segment is projected to expand at a lucrative CAGR over the forecast period owing to high prevalence of blood disorders
• North America held the dominant market share in 2017 owing to favorable reimbursement scenario and presence of sophisticated technological facilities
• Asia Pacific is projected to witness swift growth during the forecast period owing to the rising healthcare expenditure coupled with focus on quality healthcare infrastructure
• Few of the key players in hematology testing market include Beckman Coulter, Inc.;Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Siemens Healthineers; Mindray Medical International Limited; and Sysmex Corporation.

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the global hematology diagnostics market based on product, end-use, test type, and region:

Hematology Diagnostics Product Outlook (Revenue, USD Million, 2014 – 2025)

• Instrument
  • Analyzers
  • Flow cytometers
  • others
• Consumables
  • Reagents
  • Stains
  • others

Hematology Diagnostics End-use Outlook (Revenue, USD Million, 2014 – 2025)

• Hospitals
• Diagnostic labs
• Others

Hematology Diagnostics Test type Outlook (Revenue, USD Million, 2014 – 2025)

• Blood count
• Platelet function
• Hemoglobin
• Hematocrit

Hematology Diagnostics Regional Outlook (Revenue, USD Million, 2014 – 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Access Press Release of Hematology Diagnostics Market @ https://www.grandviewresearch.com/press-release/global-hematology-diagnostics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

Clinical Trial Imaging Market Expected To Witness A Substantial Growth Of USD 1.31 Billion By 2026: Grand View Research Inc.

San Francisco, 6 Nov 2020: The Report Clinical Trial Imaging Market Size, Share & Trends Analysis Report By End Use (CROs, Pharmaceutical Companies), By Service, By Modality (CT Scan, Ultrasound, MRI), And Segment Forecasts, 2018 – 2026

The global clinical trial imaging market size is expected to reach USD 1.31 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.8% during the forecast period. Increasing spending on research and development activities to develop new drugs and therapies to treat chronic diseases is boosting the market growth.

Clinical trials assist in the development, registration, and eventually access of new drugs to patients. Imaging helps in the process of drug development by offering a noninvasive evaluation of drug action and response of the tumor to treatment. Functional imaging techniques are progressively being used in early phases of clinical trials to study the initial effects of drug action on parts of tumor biology including metabolism, cellularity, and vascularity. 

Contract Research Organizations (CROs) were the most prominent end-use segment in the market in 2017. Imaging modalities are used to determine indicators of pharmacological response to therapy. Biomarkers and surrogate endpoints assist in obtaining quick results with good statistical power even in small sample sizes encouraging CROs to carry out multiple studies with reduced cost of operation.

The market in Asia Pacific is projected to witness swift growth during the forecast period as the number of CROs and pharmaceutical organizations in the region are increasing in recent past due to the low cost of labor and public and private funding offered in countries such as India and China. However, inaccessibility of trial protocols and poor quality of registered clinical trial data, results, and participant-level data undermined the potential benefits of clinical trial registration earlier. Nevertheless, the emergence of national and regional registries and ICTRP have facilitated to overcome the aforementioned barriers in APAC.

Access Research Report of Clinical Trial Imaging Market @ https://www.grandviewresearch.com/industry-analysis/clinical-trial-imaging-market

Clinical Trial Imaging Market Report Highlights

• North America dominated the market in 2017. Attaining compliance with registration requires a combination of international and local measures and remains a key challenge in many countries. However, U.S. FDA and other regulatory organizations have played a leading role in attaining accomplishments of trial registration to date and is likely to be supported in tackling such challenges in the near future
• Some of the players operating in this market are Parexel International Corporation; Intrinsic Imaging; Radiant Sage; Icon PLC; Worldcare Clinical; Bioclinica Inc.; Navitas Life Sciences; Resonance Health; Ixico PLC; and Medpace.

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the global clinical trial imaging market based on service, modalities, end-use, and region:

Clinical Trial Imaging Service Outlook (Revenue, USD Million, 2014 – 2026)   

• Clinical trial design and consultation services
• Reading and analytical Services
• Operational Imaging services
• System and technology support services
• Project and Data Management

Clinical Trial Imaging Modalities Outlook (Revenue, USD Million, 2014 – 2026)          

• Computed Tomography (CT) Scan
• MRI ( Magnetic Resonance Imaging)
• X-Ray
• Ultrasound
• Optical Coherence Tomography (OCT)
• Others (Positron Emission Tomography (PET), Single-Photon Emission Computerized Tomography (SPECT)Reading and analytical Services

Clinical Trial Imaging End-use Outlook (Revenue, USD Million, 2014 – 2026)

• Biotechnology and Pharmaceutical companies
• Medical Devices Manufacturers
• Academic and government research institutes
• Contract Research Organization (CROs)
• Others (Cosmetics and skincare industries)

Clinical Trial Imaging Regional Outlook (Revenue, USD Million, 2014 – 2026)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Access Press Release of Clinical Trial Imaging Market @ https://www.grandviewresearch.com/press-release/global-clinical-trial-imaging-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

Zika Virus Testing Market Size Is Projected To Reach USD 580.4 Million By 2027: Grand View Research Inc.

San Francisco, 5 Nov 2020: The Report Zika Virus Testing Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Amplification Testing (NAAT), Serological Testing), By Region, Vendor Landscape, And Segment Forecasts, 2018 – 2027

The global zika virus testing market size is expected to reach USD 580.4 million by 2027, according to a new report by Grand View Research, Inc., progressing at a CAGR of 7.6% during the forecast period. Zika virus outbreak in 2016 contributed to the rise in response strategies and diagnostic surveillance activities. Widespread incidence of the disease in 2016 was mostly a result of travel-based viral transmission. The recently drawn correlation between Zika virus infection and microcephaly in newborns is further stoking growth of the market. 

Spiraling demand for Zika Virus Testing stems from government-led preparedness programs and support from international organizations such as UNICEF. Stockpiling and emergency preparedness initiatives focus on endemic regions as well as immunologically naïve population subsets in the Asian and African markets, which hold high threat of future outbreaks. These developing regions, currently not classified as endemic, are host to temperature changes, humidity, and precipitation as well as reported vector presence that cumulatively provide a supportive habitat for the causative vector, Aedes aegypti mosquitoes.

Access Research Report of Zika Virus Testing Market @ https://www.grandviewresearch.com/industry-analysis/zika-virus-testing-market

Further key findings from the report suggest:

• NAAT and serological segments in the Zika Virus Testing market held nearly equal market share in 2016. However, the former was preferred for its cost effectiveness in analyzing high volume of tests during the epidemic
• Serological tests are gaining preference as they can provide differential diagnosis and are performed to detect late-stage infections
• In 2016, the U.S. states and territories dominated the market in terms of revenue. Increasing blood donation screening using individual donor NAAT tests to prevent transfusion-related disease transmission is one of key factors contributing to the market.
• Latin America followed in terms of market share as it witnessed more than 50% of the globally recorded disease incidence in 2016. Brazil’s National Development Bank announced funding worth USD 136.6 million, which will drive disease surveillance activities with improved rapid tests to fight zika virus infection in the country
• UNICEF awarded long-term arrangement contracts, effective until 2019, to Chembio Diagnostic Systems, Inc. and SD Biosensors, Inc. for the supply of ZIKV diagnostics
• In 2016, Quest Diagnostics, Inc.; Roche; and Hologic were among the leading market players with FDA-approved diagnostics under emergency use authorization

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the global Zika Virus Testing market based on test type and region:

Zika Virus Testing Test Type Outlook (Revenue, USD Million, 2016-2027)

• Nucleic Acid Amplification Testing (NAAT)
• Serological Testing

Zika Virus Testing Regional Outlook (Revenue, USD Million, 2016-2027)

• U.S. States & Territories
• Europe
• Asia Pacific
• Latin America
• Africa

Access Press Release of Zika Virus Testing Market @ https://www.grandviewresearch.com/press-release/global-zika-virus-testing-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

Women’s Health Diagnostics Market Size Is Poised To Reach USD 30.8 Billion By 2025: Grand View Research Inc.

San Francisco, 3 Nov 2020: The Report Women’s Health Diagnostics Market Size, Share & Trends Analysis Report By End Use, By Application (Cancer, Infectious Disease, Osteoporosis, Pregnancy, Prenatal), and Segment Forecasts, 2018 – 2025

The global women’s health diagnostics market size is expected to reach USD 30.8 billion by 2025, according to a new report by Grand View Research, Inc. Rising adoption of point-of-care diagnostics and growing incidence of various chronic and lifestyle diseases are among the key factors stimulating the growth of the market. Besides this, introducing various awareness programs is also anticipated to work in favor the market during the forecast period. For instance, in 2014, the European Commission launched joint action for European Guide on Quality Improvement in Comprehensive Cancer Control.

Women’s health diagnostics is witnessing high growth due to increased funding from various organizations. For instance, in May 2015, Abcodia received funding of USD 8.0 million from Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, and UCLB to launch Risk of Ovarian Cancer Algorithm (ROCA) test in the U.K. for early detection of ovarian cancer.

On the basis of end use, the market has been bifurcated into hospital & diagnostics centers and home. Hospitals and diagnostic centers accounted for a larger share in the market due to high number of visits to hospitals and more reliable detection.

The market in Asia Pacific is likely to witness significant growth over the coming years. The growth of the market can be attributed to increasing investments in healthcare, growing focus of international device manufacturers on strengthening their distribution networks within the region, and epidemiological shift from infectious diseases to chronic diseases within regional boundaries.

Access Research Report of Women’s Health Diagnostics Market @ https://www.grandviewresearch.com/industry-analysis/womens-health-diagnostics-market

Further key findings from the report suggest:

• Increasing investments by governments and private bodies and rising disposable income are providing a push to the market
• Cancer accounted for the highest share in the market in 2017. The segment will register noteworthy growth during the forecast period owing to availability of early detection tests and government initiatives to tackle cancer
• Prenatal testing is estimated to be the fastest growing segment during the same period owing to rising prevalence of prenatal diseases, increasing maternal age, surging healthcare expenditure, and development of advanced diagnostic tests
• Geographically, North America was the leading revenue contributor to the women’s health diagnostics market in 2017. It is anticipated to maintain its dominance through 2025, thanks to widening base of diagnostic and imaging centers, mounting cases of cancer, growing awareness about fertility testing, and spiraling adoption of point-of-care testing devices
• Some of the key players are Siemens Healthcare Private Limited; Hologic, Inc.;GE Healthcare; F. Hoffmann-La Roche Ltd.; bioMérieux SA; Koninklijke Philips N.V; Abbott; Becton, Dickinson and Company, Quest Diagnostics, Inc.; and PerkinElmer, Inc.

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the global women’s health diagnostics market based on application, end use, and region:

Women’s Health Diagnostics Application Outlook (Revenue, USD Million, 2014 – 2025)

• Cancer
  • Breast Cancer Testing
  • Cervical Cancer Testing
  • Ovarian Cancer Testing
• Infectious Disease Testing
• Osteoporosis Testing
• Pregnancy and Fertility Testing
• Prenatal Testing

Women’s Health Diagnostics End Use Outlook (Revenue, USD Million, 2014 – 2025)

• Hospital and Diagnostics Centers
• Home

Women’s Health Diagnostics Regional Outlook (Revenue, USD Million, 2014 – 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Access Press Release of Women’s Health Diagnostics Market @ https://www.grandviewresearch.com/press-release/global-womens-health-diagnostics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

Point-of-Care Molecular Diagnostics Market Expected To Witness A Substantial Growth Of USD 3.86 Billion By 2024: Grand View Research Inc.

San Francisco, 29 Sep 2020: The Report Point-of-Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Test Location (OTC, PoC), By Application (Infectious Diseases, Oncology), By End Use, By Technology, And Segment Forecasts, 2019 – 2024

The global point-of-care molecular diagnostics market size is anticipated to reach USD 3.86 billion by 2024 expanding at a CAGR of 14.4%, according to a new report by Grand View Research, Inc. Ongoing research & development to miniaturize molecular diagnostics testing that provides enhanced near patient testing with high accuracy and lesser turnaround times are major factors expected to reinforce the high growth potential for POC MDx products.

Growing demand for CLIA tests that are, by definition, portable and safe enough to be used in non-laboratory settings such as pharmacy clinics, physician offices, and home-care settings, is expected to drive demand in the market over the forecast period. Ongoing research and development is continually supported and funded by a number of major international entities including the governments of developed countries.

Furthermore, a growing portfolio of point-of-care testing capabilities that, had initially been focused on screening, testing, and diagnosis of infectious diseases in low-income developing countries, has been developing at a rapid pace over the past decade to expand its potential market to a broader range of medical faculties. Consequently, POC and molecular diagnosis tests are available and/or are under development for cardiology monitoring, oncology testing, and hematology testing.

Recent advances in the development of microfluidics and genetic sequencing instrumentation pave the way for development of cost-effective, highly accurate and rapid testing platforms, which are able to be used as true POC systems. This is a key factor that significantly contributes towards the favorably funded, high growth potential environment prevalent in the PoC molecular diagnostics market.

Access Research Report of Point-of-Care Molecular Diagnostics Market @ https://www.grandviewresearch.com/industry-analysis/point-of-care-poc-molecular-diagnostics-market

Further key findings from the study suggest:

• Application of POC MDx tests for infectious diseases accounted for over 45% of market revenue in 2018 due to the presence of many major market entities with an extensive product portfolio
• Growing burden of infectious diseases in both developing and developed countries is another factor responsible for the dominance of this segment
• PCR-based POC tests is the largest revenue generating segment of the market in 2018. Widespread usage of PCR-based techniques for molecular diagnosis and commercialization of POC real time PCR products have provided ample opportunities for segment growth
• North America was the largest region and accounted for 43.5% of the global revenue share due to the presence of technologically advanced medical framework, high R&D investments by governments and private organizations for the development of POC MDx tests
• Key companies in the market include Johnson & Johnson; Danaher Corp.; Cepheid, Inc.; Bio-Rad Laboratories, Inc.; bioMerieux; Becton, Dickinson and Company; F. Hoffmann-La Roche AG; Bayer HealthCare Pharmaceuticals LLC ; Alere, Inc.; (Abbott), and Abbott Laboratories

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the global PoC molecular diagnostics market on the basis of application, technology, test location, end use, and region:

PoC Molecular Diagnostics Application Outlook (Revenue, USD Million, 2013 – 2024)

• Infectious Diseases
• Oncology
• Hematology
• Prenatal Testing
• Endocrinology
• Other Applications

PoC Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2013 – 2024)

• PCR-based
• Genetic Sequencing-based
• Hybridization-based
• Microarray-based

PoC Molecular Diagnostics Test Location Outlook (Revenue, USD Million, 2013 – 2024)

• Over-the-Counter (OTC)
• PoC

PoC Molecular Diagnostics End Use Outlook (Revenue, USD Million, 2013 – 2024)

• Decentralized Labs
• Hospitals
• Homecare
• Assisted Living Healthcare Facilities
• Other Uses

PoC Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2013 – 2024)

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Access Press Release of Point-of-Care Molecular Diagnostics Market @ https://www.grandviewresearch.com/press-release/global-point-of-care-poc-molecular-diagnostics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com